ArticleAmerican journal of translational research2018
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Efficacy of Xiaoyao-san preparations in treating Hashimoto's thyroiditis: a meta-analysis and systematic review.Frontiers in pharmacology · 2025Pooled it
- Efficacy and safety ofFrontiers in pharmacology · 2023Pooled it
- Ophiocordyceps indica from the Indian Himalayas Ameliorates the IgA Nephropathy in Mice.Applied biochemistry and biotechnology · 2026Article
- Therapeutic Mechanisms of Jinshuiqing in IgA Nephropathy: A Transcriptomic Analysis.Medical science monitor basic research · 2025Article
- Effect of time-weighted average 25(OH)D on the occurrence of major adverse kidney events in IgA nephropathy-from a 10-year population-based cohort study.Frontiers in nutrition · 2025Article
- RNA-Seq-Based Transcriptome Analysis of Chinese Cordyceps Aqueous Extracts Protective Effect against Adriamycin-Induced mpc5 Cell Injury.International journal of molecular sciences · 2024Article
- Use of bailing capsules (cordyceps sinensis) in the treatment of chronic kidney disease: a meta-analysis and network pharmacology.Frontiers in pharmacology · 2024Review
- Classification, function, and advances in tsRNA in non-neoplastic diseases.Cell death & disease · 2023Review
- Bailing capsule (Frontiers in pharmacology · 2022Article
- Interleukin-22 in Renal Protection and Its Pathological Role in Kidney Diseases.Frontiers in immunology · 2022Review
- Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases.Frontiers in immunology · 2021Review
- Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis.Experimental and therapeutic medicine · 2019Article
- Simultaneous Quantification of Adenosine and Deoxyadenosine Isomers in Foods with High Sensitivity.Analytical methods : advancing methods and applications · 2019Article
- Streptococcus may aggravate inflammatory damage in chronic nephritis via the chemotaxis of Th22 cells.American journal of translational research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy is the most common form of primary glomerulonephritis and an important cause of kidney failure. Cordyceps sinensis (CS) is a parasitic fungus that has a long history of use in Chinese medicine for the treatment of nephritis. Interleukin (IL)-22-producing helper T cells (Th22 cells) have been reported to be involved in lgA nephropathy. Th22 cells link the immune response to tissue inflammation. To elucidate the possible efficacy and mechanisms by which CS counteracts nephritis, we established an IgA nephropathy model in 6-week-old female BALB/c mice. The mice were randomly separated into 3 groups, the normal control, IgA nephropathy and CS (5 mg/kg/d) treatment groups. The Th22 cell frequencies and the relative pathological and cytokine changes were measured with flow cytometry, whereas the serum chemokine ligand 27 (CCL27) and IL-22 concentrations were detected with ELISA. The Th22 cell frequency decreased after 1 month of CS therapy. Additionally, mesangial cell proliferation decreased. Moreover, the chemokine receptor type 10 (CCR10), CCL27 and IL-22 expression levels were significantly reduced. In conclusion, CS may modulate the chemotaxis of Th22 cells to suppress inflammatory responses in IgA nephropathy.
Indexed as
Identifiers
29636875PMC5883126W2944765696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.